Literature DB >> 30228690

Hypersomnia.

Pradeep C Bollu1, Sivaraman Manjamalai2, Mahesh Thakkar3, Pradeep Sahota4.   

Abstract

Adequate alertness is necessary for proper daytime functioning. Impairment of alertness or increase in sleepiness results in suboptimal performance and adversely affects the quality of life. While some causes of somnolence are intrinsic to the brain circuitry and neurochemical architecture, others are due to maladaptive behaviors and disorders affecting the normal sleep homeostasis. Identification of the problem and understanding the underlying etiology is the key to timely treatment and better outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 30228690      PMCID: PMC6139790     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  23 in total

1.  Depresssion in narcolepsy and hypersommia.

Authors:  B Roth; S Nevsimalova
Journal:  Schweiz Arch Neurol Neurochir Psychiatr       Date:  1975

2.  Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury.

Authors:  C R Baumann; R Stocker; H-G Imhof; O Trentz; M Hersberger; E Mignot; C L Bassetti
Journal:  Neurology       Date:  2005-07-12       Impact factor: 9.910

3.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

4.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

5.  Adenosine A2A receptor deficiency attenuates the somnogenic effect of prostaglandin D2 in mice.

Authors:  Bin-Jia Zhang; Zhi-Li Huang; Jiang-Fan Chen; Yoshihiro Urade; Wei-Min Qu
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

Review 6.  Excessive daytime sleepiness in parkinsonism.

Authors:  Isabelle Arnulf
Journal:  Sleep Med Rev       Date:  2005-04-26       Impact factor: 11.609

7.  Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?

Authors:  Hagop S Akiskal; Franco Benazzi
Journal:  J Affect Disord       Date:  2005-02       Impact factor: 4.839

8.  Sleep in remitted bipolar disorder: a naturalistic case-control study using actigraphy.

Authors:  Pierre Alexis Geoffroy; Carole Boudebesse; Frank Bellivier; Mohamed Lajnef; Chantal Henry; Marion Leboyer; Jan Scott; Bruno Etain
Journal:  J Affect Disord       Date:  2014-01-30       Impact factor: 4.839

9.  Predictors of residual sleepiness in adequately treated obstructive sleep apnoea patients.

Authors:  I Koutsourelakis; E Perraki; N T Economou; P Dimitrokalli; E Vagiakis; C Roussos; S Zakynthinos
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

10.  Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure.

Authors:  Merce Gasa; Renaud Tamisier; Sandrine H Launois; Marc Sapene; Francis Martin; Bruno Stach; Yves Grillet; Patrick Levy; Jean-Louis Pepin
Journal:  J Sleep Res       Date:  2013-02-15       Impact factor: 3.981

View more
  2 in total

1.  Dysfunctions of the paraventricular hypothalamic nucleus induce hypersomnia in mice.

Authors:  Chang-Rui Chen; Yu-Heng Zhong; Shan Jiang; Wei Xu; Lei Xiao; Zan Wang; Wei-Min Qu; Zhi-Li Huang
Journal:  Elife       Date:  2021-11-17       Impact factor: 8.140

2.  Case Report: Dysfunction of the Paraventricular Hypothalamic Nucleus Area Induces Hypersomnia in Patients.

Authors:  Zan Wang; Yu-Heng Zhong; Shan Jiang; Wei-Min Qu; Zhi-Li Huang; Chang-Rui Chen
Journal:  Front Neurosci       Date:  2022-03-14       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.